What Happened?
Redwood City, CA-based Menlo-Therapeutics Appointed Steve Basta as Chief Executive Officer
About the Company
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
About the Person
Steve Basta is Chief Executive Officer at Menlo Therapeutics. Previously, Steve held various senior HR leadership roles in the industry.
Info Source
News
Short Profile